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Abstract
The presence of autoantibodies in New Zealand Black (NZB) mice suggests a B cell tolerance defect however the nature of
this defect is unknown. To determine whether defects in B cell anergy contribute to the autoimmune phenotype in NZB
mice, soluble hen egg lysozyme (sHEL) and anti-HEL Ig transgenes were bred onto the NZB background to generate double
transgenic (dTg) mice. NZB dTg mice had elevated levels of anti-HEL antibodies, despite apparently normal B cell functional
anergy in-vitro. NZB dTg B cells also demonstrated increased survival and abnormal entry into the follicular compartment
following transfer into sHEL mice. Since this process is dependent on BAFF, BAFF serum and mRNA levels were assessed and
were found to be significantly elevated in NZB dTg mice. Treatment of NZB sHEL recipient mice with TACI-Ig reduced NZB
dTg B cell survival following adoptive transfer, confirming the role of BAFF in this process. Although NZB mice had modestly
elevated BAFF, the enhanced NZB B cell survival response appeared to result from an altered response to BAFF. In contrast,
T cell blockade had a minimal effect on B cell survival, but inhibited anti-HEL antibody production. The findings suggest that
the modest BAFF elevations in NZB mice are sufficient to perturb B cell tolerance, particularly when acting in concert with B
cell functional abnormalities and T cell help.
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Introduction
Systemic lupus erythematosus (SLE) is a multi-system autoim-
mune disease characterized by production of pathogenic anti-
nuclear antibodies (ANA), resulting in the formation of immune
complexes. The production of ANA suggests a loss of tolerance to
nuclear antigens, however the precise defects leading to this
breach remain unclear. NZB mice develop high titer anti-RBC
and -ssDNA antibodies (Abs) leading to a Coomb’s positive
hemolytic anemia and mild glomerulonephritis [1]. One of the
characteristics of these mice is polyclonal B cell activation, similar
to that observed in human SLE, suggesting that characterization of
the defects in these mice may be particularly relevant to the
human disease [2-7].
Induction and maintenance of B cell tolerance involves a series
of checkpoints acting through multiple phases of B cell
development [8-10]. We have previously shown that deletion of
B cell receptor (BCR)-engaged early transitional (T1) B cells is
defective in NZB mice [11]. Since normally these self-reactive B
cells are rendered anergic and fail to enter the mature re-
circulating B cell pool [12–14], the presence of activated auto-
reactive B cells in the peripheral repertoire of these mice suggests
that there are additional B cell tolerance defects.
Entry of transitional B cells into the mature B cell re-circulating
pool is critically-dependent upon B cell-activating factor (BAFF)
[15]. Patients with SLE exhibit elevated levels of serum BAFF
[16–18] and over-expression of BAFF in BAFF transgenic (Tg) mice
leads to development of a lupus-like phenotype [19,20]. Based upon
findings in these mice, it has been proposed that increased levels of
BAFF breach B cell tolerance in lupus by enhancing survival of self-
reactive B cells, thus allowing their abnormal entry into the mature
follicular compartment where they can receive T cell help [21].
However,itisunclearwhetherthelevels inlupuspatients, whichare
considerably less than seen in BAFF transgenic mice, are sufficient
to produce these abnormalities.
Here, we have investigated the induction and maintenance of B
cell anergy in NZB mice. Anti-hen egg white lysozyme (HEL) Ig
and soluble HEL (sHEL) transgenes (Tg) were crossed onto the
NZB background and intercrossed to produce double Tg (dTg)
mice, a well-characterized model of B cell anergy [22]. Although B
cells in NZB dTg mice appeared phenotypically and functionally
anergic, these mice produced high serum levels of anti-HEL Ab,
suggesting that B cell anergy had been overcome. Using adoptive
transfer experiments, we show that NZB dTg B cells demonstrate
enhanced survival and abnormal entry into the follicular
compartment, similar to that seen for BAFF Tg mice. We further
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11691demonstrate that the increased survival of transferred dTg B cells
is BAFF-dependent and that BAFF cooperates with T cells to
breach tolerance in these mice. Although NZB mice demonstrated
modest increases in BAFF, the increased survival of NZB dTg B
cells appeared to arise from a heightened response to BAFF.
Results
NZB dTg mice produce anti-HEL autoAb
On the B6 genetic background, introduction of the anti-HEL
IgTg results in high serum levels of anti-HEL Ab, which are absent
in B6 dTg mice as a consequence of B cell anergy [22]. NZB IgTg
mice produce higher levels of anti-HEL Ab than their B6 IgTg
counterparts (Figure 1A), which we have previously shown to
reflect the relative inability of the anti-HEL Ig transgene to
normalize the polyclonal B cell activation phenotype in NZB mice
[23]. NZB dTg mice produced significant levels of HEL-specific
IgM
a Ab, which in some mice approached the levels seen in B6
IgTg mice (Figure 1A). Consistent with the elevated serum anti-
HEL Ab levels, increased numbers of anti-HEL Ab-producing
cells were detected in the spleens (Figure 1B) and bone marrow
(data not shown) of NZB dTg mice. Immunofluorescent
microscopy of frozen splenic sections also revealed HEL-positive
cells within the marginal zone, red-pulp, bridging channels, and T
cell zone of NZB, but not B6 dTg mice. These cells were IgM
abright
suggesting that they were plasmablasts (data not shown).
As regulation of plasma cell differentiation for self-tolerant B
lymphocytes occurs at the transition from the early to late
pre-plasma cell stage [24], we examined these cell populations in
NZB dTg mice. As shown in Figure 1C, early pre-plasma cells
(CD21
2/+CD138
int) were found in the bone marrow of both B6
and NZB dTg mice, but NZB dTg mice had a significantly higher
proportion of these cells. In addition, a marked increase in
CD138
high late pre-plasma cells was seen in NZB dTg mice.
Similar findings were observed for IgM
a+ or HEL-binding B cells.
Thus, the immune mechanisms preventing differentiation of
anergic B cells to late pre-plasma and Ab-forming cells are
defective in NZB mice.
NZB dTg B cells are phenotypically and functionally
anergic
As shown in Table 1, over 99% of B cells in both B6 and NZB
IgTg mice expressed the IgM
a transgenic heavy chain and bound
to HEL. NZB dTg mice had similar reductions in B cell numbers
and cell surface IgM
a expression to B6 dTg mice, consistent with
an anergic phenotype [25,26] (Table 1). Down-regulation of cell
surface IgM
a in dTg mice results from chronic antigen-
engagement and reflects both the serum concentration of HEL
and signaling capacity of the B cell [26–28]. Serum from NZB and
B6 dTg mice down-regulated IgM
a equivalently on IgTg B cells in-
vitro with both B6 and NZB IgTg B cells demonstrating similarly
reduced levels of IgM
a. Thus, both the serum concentration of
HEL and signaling threshold for IgM
a down-regulation appear to
be the same in B6 and NZB dTg mice.
Chronicantigen-engagement ofB cells with HELinB6 dTgmice
results in up-regulation of Rag expression leading to attempted
receptor editing [10,13]. When these endogenous light chains
impair HEL binding they can be detected as IgM
a+HEL
low/2 cells,
whose cell surface expression of IgM
a is higher than anergic dTg B
cells [10]. Consistent with previous reports, there was an increased
proportion of IgM
a+HEL
low/2 B cells in B6 dTg as compared to B6
IgTg mice (Table 1). The proportion of these cells was significantly
less in NZB dTg mice, suggesting that there is reduced induction of
receptor editing and/or production of effectively competing light
chains in these mice.
Anergic B cells do not proliferate and demonstrate impaired
induction of CD86 in response to antigenic stimulation [29,30].
Therefore, sorted B cells were stimulated in-vitro with various
concentrations of HEL together with a sub-mitogenic concentra-
tion of LPS. As shown in Figure 2A, B cells from both B6 and NZB
IgTg mice showed a strong proliferative response to HEL in a
concentration-dependent fashion. In contrast, neither B6 nor NZB
Figure 1. Breach of B cell anergy in NZB dTg mice. (A) Serum
levels of IgM
a anti-HEL antibodies in 8–12 wk old B6 and NZB non-Tg
(nTg), IgTg and dTg mice. (B) Presence of anti-HEL Ab-producing cells in
NZB dTg mice. The number of anti-HEL Ab-forming cells was
determined by ELISpot in 8-12 wk old B6 and NZB IgTg and dTg mice.
Horizontal lines represent the mean for each group examined. (C)
Presence of an increased proportion of early (CD21
+CD138
int) and late
(CD138
high) pre-plasma cells in NZB dTg mice. Bone marrow cells from
8 wk old B6 and NZB IgTg and dTg mice were stained with anti-B220, -
CD138, and -CD21 Abs and analyzed by flow cytometry. Dot plots are
gated on the B220
+ population and numbers indicate the percentage of
gated cells in each region. Asterisks indicate the significance level for
comparison between B6 and NZB mice as determined by the Mann-
Whitney test: * p,0.05, ** p,0.005, *** p,0.0005.
doi:10.1371/journal.pone.0011691.g001
B Cell Tolerance in NZB Mice
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HEL tested, suggesting that NZB dTg B cells are equivalently
anergic to their B6 counterparts. Consistent with this observation,
induction of CD86 expression following overnight incubation with
HEL was similarly reduced for B6 and NZB dTg B cells, as
compared to corresponding IgTg controls (Figure 2B). Thus, B
cells from NZB dTg mice are both phenotypically and functionally
anergic.
NZB dTg mice have an expansion of T2 cells
To investigate whether the breakdown of anergy in NZB dTg
mice was accompanied by a failure to exclude anergic B cells from
the marginal zone, we used anti-B220 and -CD21 in combination
with anti-CD24 or -CD23 to define splenic B cell subsets.
Although NZB IgTg mice have an increased proportion of
marginal zone (CD21
hiCD23
2) B cells as compared to their B6
counterparts [23], the proportion of marginal zone and marginal
zone precursor (CD21
hiCD23
+ or CD21
hiCD24
hi) cells were
significantly reduced in NZB dTg mice comparably to B6 dTg
mice (Table 1). These findings suggest that anergic B cells are
appropriately excluded from the marginal zone in NZB mice.
Consistent with this, immunofluorescence microscopy revealed no
B220
+HEL
+ B cells within the marginal zone of NZB dTg mice
(data not shown). Nevertheless, NZB dTg mice had an increased
proportion of T2 (CD21
intCD24
hi) and follicular B cells (Fo,
CD21
intCD24
int), which appeared to result from a shift towards a
more mature phenotype within the transitional compartment
(Table 1).
NZB dTg B cells demonstrate enhanced survival
following transfer into sHEL recipients
Although the expansion of T2 cells in NZB dTg mice occurred
within a monoclonal repertoire, we questioned whether this might
reflect a failure to exclude and/or delete anergic B cells. To
address this possibility, we performed adoptive transfer experi-
ments in which IgTg or dTg B cells were transferred into sHEL
recipient mice. Freshly isolated T cell-depleted splenocytes were
CFSE-labeled and the fate of the transferred cells determined by
flow cytometry and immunofluorescence microscopy. Consistent
with previous reports by ourselves and others, the majority
(approximately 80–90%) of B6 IgTg or dTg B cells transferred into
sHEL B6 were eliminated 3 days following transfer (Figure 3A)
[14,31]. In contrast, transferred NZB IgTg and dTg B cells
demonstrated significantly enhanced survival, with 35–50% of the
cells remaining on day 3. Immunofluorescence microscopy
revealed that some of these surviving cells migrated into the B
cell follicle (Figure 3B).
We have previously shown that NZB IgTg B cells not only
survive but also proliferate and differentiate into anti-HEL Ab-
producing cells within 3 days of being transferred into sHEL NZB
recipient mice [31]. On day 7, Ab production was further
augmented and accompanied by recruitment of IgTg B cells into
germinal centers. This abnormal response resulted from an
intrinsic defect in NZB B cells and was CD4
+ T cell- and
MHC-dependent. Unlike their IgTg counterparts, NZB dTg B
cells failed to proliferate and did not differentiate into Ab-forming
cells by day 3. In addition, their survival was less dependent on
CD4
+ T cells than their IgTg counterparts (Figure 3C). Never-
theless, by 7 days post transfer dTg B cells had been recruited into
germinal centers, although at a considerably reduced extent than
seen following transfer of IgTg B cells (Figure 3B). No surviving B6
dTg B cells could be detected at day 7. This suggests that immune
mechanisms that lead to exclusion and elimination of anergic B
cells from the peripheral repertoire are defective in NZB mice and
that this permits anergic B cells to access T cell help, albeit
inefficiently.
To further investigate the role of T cells in the breach of
tolerance, young NZB dTg mice were given regular injections of
purified anti-CD4 mAb to deplete CD4
+ T cells, or PBS alone.
Treatment with anti-CD4 mAb significantly reduced anti-HEL Ab
Table 1. Comparisons of splenic populations in B6 and NZB nTg, IgTg, and dTg mice.
B6 NZB
nTg (N=4) IgTg (N=11) dTg (N=7) nTg (N=4) IgTg (N=17) dTg (N=11)
# splenocytes per spleen (x 10
6) 32.4466.84 38.76612.99 31.5469.90 50.8867.16 * 46.31612.34 35.4614.44
# B220
+ cells per spleen (x 10
6) 20.2863.35 22.4768.20 11.26±3.53 21.6567.85 21.6567.85 8.62±3.08
% B220
+ 62.9563.16 57.2663.77 35.64±4.53 41.1565.32 * 46.3768.17 25.96±8.40 **
%I g M
a+ N.D. 99.7460.37 96.13±0.73 N.D. 99.4760.36 91.60±2.77 ***
IgM
a MFI N.D. 14286276.7 142.4±54.51 N.D. 860.86155.8 *** 115.5±83.02
%I g M
a+ HEL
+ N.D. 97.2161.90 88.36±4.02 N.D. 97.7462.00 87.48±4.31
%I g M
a+ HEL
low/2 N.D. 2.9062.12 7.78±3.83 N.D. 1.7361.92 4.23±2.10 *
%I g M
a2 HEL
+ N.D. 0.01860.033 0.87±0.52 N.D. 0.04760.061 3.02±1.73 **
%I g M
a2 HEL
low/2 N.D. 0.1860.30 2.57±0.70 N.D. 0.4460.31 4.83±1.97 **
% T1 (CD21
low CD24
hi) N.D. 19.0365.31 39.26±8.84 N.D. 13.9865.17 18.86±6.06 ***
% T2 (CD21
int CD24
hi) N.D. 6.8463.03 11.36±3.73 N.D. 7.3364.62 18.37±7.48 *
% MZ/MZP (CD21
hi CD24
hi) N.D. 18.18±3.13 7.6563.04 N.D. 33.85±12.87 * 11.4564.96
% Fo (CD21
int CD24
int) N.D. 50.18±6.47 29.93±8.96 N.D. 34.84±7.46 ** 41.21±8.08 *
Results are mean 6 SD. Numbers in brackets denote the number of 2 to 3 mo old female mice examined in each group. The proportion of anti-IgM
a- and/or HEL-
staining and B cell subsets are expressed as a percentage of the B220
+ population. Asterisks indicate the significance level for comparison of NZB non-Tg with B6 non-
Tg, NZB IgTg with B6 IgTg, or NZB dTg with B6 dTg mice, as determined by the Mann-Whitney test: * p,0.05, ** p,0.005, *** p,0.0005. Numbers are shown in bold if
there is a significant difference (p,0.05) between IgTg and dTg of the same strain. N.D. not done. B cell subsets were identified using combinations of anti-B220, -CD24
and -CD21. T1 = early transitional, T2 = late transitional, MZ = marginal zone, FO = follicular, MZ precursor = MZP.
doi:10.1371/journal.pone.0011691.t001
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+ T
cell help contributes to the breach of tolerance in these mice. In
support of this concept staining of spleen sections from NZB dTg
mice revealed IgM
a+HEL
+-staining germinal centers (data not
shown) which did not appear to result from activation of cells that
co-expressed IgM
b.
Serum BAFF is significantly elevated in NZB mice and
promotes NZB dTg B cell survival following adoptive
transfer
Since BAFF can rescue anergic self-reactive B cells from
deletion by permitting their entry into the follicular and marginal
zone B cell compartments [21,32], we questioned whether NZB
mice had elevated levels of BAFF. As shown in Figure 4A, 6–
12 wk NZB non-Tg, IgTg, and dTg mice had elevated levels of
BAFF as compared to their B6 counterparts. The increased levels
of BAFF in NZB IgTg and dTg mice did not result from
differences in the number of B cells, as splenic baff RNA expression
was also significantly increased (Figure 4B).
To determine whether the increased survival of adoptively
transferred NZB dTg B cells was BAFF-dependent, NZB sHEL
recipient mice were injected with TACI-Ig, or PBS alone, 1 day
before transfer of CFSE-labelled dTg B cells and were analyzed 3
days later. In 2 of 3 recipient mice, a single TACI-Ig injection
resulted in significant depletion (.50%) of the marginal zone
precursor and marginal zone B cell populations in recipient mice.
In both of these mice, survival of transferred dTg B cells was
reduced two-fold as compared to PBS-injected recipients
(Figure 4C). Thus, the increased survival of NZB dTg B cells is
BAFF-dependent.
Heightened survival response of NZB B cells to BAFF
The increased survival of NZB dTg B cells following transfer
into sHEL recipients was not solely due to increased levels of
BAFF in the NZB environment, because NZB dTg B cells also
demonstrated enhanced survival following transfer into sHEL
(NZB x B6)F1 recipients (see Figure 3A). This finding raised the
possibility that NZB dTg B cells have a heightened response to
BAFF leading to their increased survival. Since BAFF has been
shown to enhance B cell survival by at least two mechanisms:
down-regulation of the pro-apoptotic molecule Bim [32,33] and
up-regulation of anti-apoptotic molecules such as Bcl-2 [15,34,35],
we hypothesized that the increased survival of NZB dTg B cells
results from altered expression of these molecules. To assess this
possibility, B cells from B6 and NZB non-Tg, IgTg or dTg mice
were stimulated with HEL in the presence or absence of BAFF for
20 hr and expression of Bim or Bcl-2 assessed using flow
cytometry. Bim expression was unaffected by the presence or
absence of BAFF or HEL for both B6 and NZB B cells at 20 hr
(data not shown). Although incubation of NZB IgTg B cells with
BAFF also did not result in significant changes in Bcl-2 expression
at 20 hr, Bcl-2 expression was induced by incubation with HEL
(Figure 5A). At 96 hr, Bcl-2 expression was significantly increased
in IgTg B cells incubated with BAFF in the presence or absence of
HEL (Figure 5A). Notably, NZB dTg B cells responded similarly
to IgTg B cells with increased expression of Bcl-2 in response to
HEL at 20 hr and increased expression of Bcl-2 in response to
BAFF and HEL at 96 hr. Incubation of B6 dTg B cells with HEL
and/or BAFF resulted in minimal changes in the expression of
Bcl-2 at 20 or 96 hr. This was not due to the altered proportions of
B cell subsets in NZB IgTg and dTg mice, because increased
expression of Bcl-2 was seen in all peripheral B cell subsets (T1,
T2, MZP and Fo) of these mice (Figure 5B). These findings suggest
that the increased survival response of NZB dTg B cells results
from altered expression of Bcl-2, but not Bim. Notably, there was a
trend to increased expression of BAFF-R on all peripheral B cell
populations in NZB IgTg and dTg mice, as compared to their B6
counterparts. This appeared to reflect an increased proportion of
cells expressing BAFF-R rather than a shift in overall staining
within these populations and did not arise from differences in
BAFF binding between these mice, as staining with the anti-BAFF-
R antibody is not affected by binding to BAFF. Thus, it is likely
that the altered BAFF response in NZB dTg mice arises at least in
part from increased BAFF-R expression.
Discussion
In this study, we used a well-characterized transgenic model of
B cell anergy to explore the mechanisms that lead to the
breakdown of B cell tolerance in NZB mice. We show that
although dTg B cells in NZB mice appear functionally and
phenotypically anergic, they are recruited into germinal centers
and/or differentiate into autoAb producing cells. Production of
autoAbs in these mice was T cell-dependent. Similar to our
previous findings for NZB IgTg B cells, NZB dTg B cells
demonstrated increased survival following transfer into sHEL
recipients. However, in contrast to NZB IgTg B cells, the
increased survival of NZB dTg B cells was relatively T cell-
independent and required BAFF. Although serum BAFF levels
Figure 2. NZB dTg B cells appear functionally anergic in-vitro.
(A) Sorted B cells from IgTg and dTg B6 or NZB mice were stimulated in-
vitro with increasing concentrations of HEL (0 to 1 mg/ml) together with
a submitogenic concentration of LPS (50 ng/mL). B cell proliferation
was measured by [
3H]-thymidine incorporation at 36 h by pulsing the
cells overnight with 1 mCi/well. Uptake of [
3H]-thymidine was quantified
using a scintillation counter and expressed as mean cpm 6 SD of
triplicate wells. Results are representative of three independent
experiments. (B) The percentage of CD86
+ cells was measured 16 h
after stimulation with 1 mg/ml HEL, gating on the B220
+IgM
a+
population.
doi:10.1371/journal.pone.0011691.g002
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appeared to arise from an altered response to BAFF resulting in
increased expression of Bcl-2. Thus, BAFF and T cells cooperate
to overcome tolerance in NZB dTg mice in the setting of
abnormal B cell function.
While our findings suggest a role for BAFF in the breach of
tolerance in NZB dTg mice they do not precisely recapitulate
those in BAFF-Tg dTg mice. Whereas, dTg B cells from BAFF-Tg
mice have an increased capacity to upregulate CD86 in response
to HEL stimulation (21), NZB dTg B cells retain their anergic
phenotype. This occurs despite evidence for increased maturation
of B cells in NZB dTg mice, suggesting that entry into the mature
B cell pool is insufficient to restore responsiveness to HEL in dTg
B cells. In addition, production of autoAb in NZB dTg mice is T
cell-dependent, while T cells are not required for the breach of
tolerance in BAFF-Tg dTg mice. It is likely that these differences
result from the considerably lower (5–10 fold) levels of BAFF in
NZB as compared to BAFF-Tg mice (unpublished observations)
together with the presence of additional signalling abnormalities in
NZB dTg lymphocytes.
All of the B cell populations examined demonstrated increased
expression of Bcl-2 following antigen-receptor engagement in the
presence of BAFF in-vitro. We have previously shown that NZB
mice have an increased proportion of T1 B cells that demonstrate
features of Ag engagement and express high levels of Bcl-2. The
findings reported herein suggest that altered BAFF signalling
contributes to this phenotype and may act to enhance entry of self-
reactive B cells into more mature B cell compartments. In support
of this conclusion, the proportion of T2 and follicular B cells was
increased in NZB dTg mice as compared to B6 controls and in our
adoptive transfer experiments the majority of residual cells on day
3 following BAFF blockage were CD21
low, indicating that BAFF is
required to increase the survival of T2 and mature cells in these
mice [36].
Studies suggest that over-expression of anti-apoptotic Bcl-2
family members, while enhancing cell survival, are not sufficient to
overcome anergy [13,37]. Therefore, it is probable that other
immune abnormalities contribute to the breach of tolerance in
NZB dTg mice. In NZB dTg mice, production of IgM anti-HEL
Ab was accompanied by increased numbers of anti-HEL Ab-
Figure 3. Increased survival of NZB dTg B cells following transfer into sHEL recipients. (A) Percent B220
+ CFSE
+ B cells surviving in sHEL
recipient mice expressed as a percentage of survival in non-Tg mice, 3 d following transfer of T cell-depleted CFSE-labelled splenocytes from B6 or
NZB, IgTg or dTg mice. Open circles indicate B6 mice and filled circles NZB mice, with horizontal lines representing the mean. Asterisks indicate the
significance level as determined by the Mann-Whitney test: * p,0.05, ** p,0.005, *** p,0.0005. (B) Immunofluorescence microscopy of spleens from
sHEL B6 or NZB mice, 3 or 7 d following transfer of T cell-depleted CFSE-labelled splenocytes from dTg mice. Sections were stained with anti-B220 or
PNA, and anti-IgM
a. Arrows indicate IgM
a+ cells in the B cell follicle (d 3) or germinal center (d 7). (C) B cell survival following transfer into NZB sHEL
recipient mice injected with PBS alone (No Ab) or anti-CD4 Ab. Open circles indicate NZB IgTg mice and filled circles NZB dTg mice. % differences in
the survival of transferred cells due to CD4
+ T cell depletion: NZB IgTg =20.1761.18; NZB dTg =4.5560.67. (D) Serum IgM
a anti-HEL Ab production
following depletion of CD4
+ T cells in NZB dTg mice. Mice were injected with anti-CD4 mAb or PBS beginning 8 wks of age and bled every 2 weeks
until 14 wks of age. P values were calculated using a two way ANOVA followed by Bonferroni post-hoc analysis.
doi:10.1371/journal.pone.0011691.g003
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high)
in the bone marrow. Since plasma cell differentiation of self-
tolerant B cells is regulated at the early to late pre-plasma cell stage
[24], our findings indicate that this tolerance checkpoint is
defective in NZB mice. Given that anti-HEL Ab production is T
cell-dependent in NZB dTg mice, it is likely that T cell signals play
an important role in the generation of this phenotype. We have
previously shown that NZB resting B cells are hyper-responsive to
T cell signals, such as those delivered by CD40 and T cell
cytokines [38]. Although anergic B cells have a block in BCR-
mediated signal transduction, they retain the ability to respond to
CD40L and T cell cytokines such as IL-4 [29]. Consequently,
NZB B cell hyper-responsiveness to T cell-derived signals could
allow the dTg B cells to respond to the limited T cell help
available, resulting in their differentiation to the late pre-plasma
stage, Ab-producing cells, and recruitment into germinal centers.
It is likely that the increased proportion of T2 and follicular B cells
in NZB dTg mice facilitates these interactions as studies show that
T1 B cells do not respond efficiently to T cells [36]. Notably,
chronic anti-CD4 treatment of NZB dTg mice resulted in a slight
reduction in the proportion of CD21
int and enrichment in the
proportion of CD21
low cells, suggesting that CD4
+ T cells act to
promote cell survival of the T2 and follicular B cell compartments
similar to BAFF.
It is possible that the increased levels of BAFF and/or BAFF
hyper-responsiveness, also contribute to the breach of B cell
anergy in NZB dTg mice. BAFF has been shown to act as a
survival factor for pre-plasma and plasma cells [39,40], and thus
could directly facilitate survival of late pre-plasma and Ab-
producing cells in these mice. Additionally, as BAFF promotes
survival of B cells during selection in germinal centers, the BAFF
abnormalities in NZB dTg mice could prevent death of HEL-
reactive B cells in the germinal centers [41,42], augmenting T cell-
dependent production of anti-HEL Ab in these mice [43,44]. In
support of the latter possibility, it is notable that several NZB dTg
mice produced high levels of IgA anti-HEL Ab, which is
augmented by BAFF, in the absence of significant amounts of
IgG anti-HEL Ab, where BAFF plays a relatively minor role
(unpublished observation) [45].
It has been suggested that a polymorphism in the promoter
region of the fcgr2b gene that leads to reduced expression of
FccRIIb in germinal centre B cells, may contribute the breach of
tolerance in NZB mice [46,47]. Genetic manipulations that
increase expression of FccRIIb have been shown to reduce IgG
autoantibody production in several other lupus-prone mouse
models [48]. However, subsequent studies have indicated that this
does not result from restoration of a generalized B cell tolerance
defect, but instead from the effect of FccRIIb on differentiation to
Figure 4. Elevated BAFF levels in NZB mice enhance survival of transferred NZB dTg B cells. (A) Serum BAFF levels in 6–12 wk old non-Tg
(nTg), IgTg and dTg, B6 and NZB mice. (B) Baff mRNA expression in the splenocytes of 8–14 wk old non-Tg (nTg), IgTg and dTg, B6 and NZB mice.
Horizontal lines represent the mean for each group examined. Significant p values for the difference between B6 and NZB mice are shown and were
determined by one way ANOVA test (Kruskal-Wallis test) followed by Dunns’ post test. (C) NZB sHEL recipient mice were injected with TACI-Ig or PBS
alone, 1 d before transfer of CFSE-labelled NZB dTg B cells. Splenocytes were analyzed 3 d later by flow cytometry. Numbers indicate the percentage
of surviving cells, determined by the ratio of CFSE
+ B220
+ cells to CFSE
+B220
- cells as compared to a NZB non-Tg control. Asterisks indicate the
significance level for comparison between B6 and NZB mice as determined by the Mann-Whitney test: * p,0.05, ** p,0.005, *** p,0.0005.
doi:10.1371/journal.pone.0011691.g004
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[49,50]. Our findings indicate that there is a more generalized
breach of tolerance in NZB mice that impacts on survival of self-
reactive B cells and their recruitment into the germinal centre and
antibody forming compartments.
It is likely that our findings are relevant to human SLE.
Although elevated levels of BAFF are seen some SLE patients [16–
18], many patients have little or no elevation of serum BAFF. Our
findings suggest that even in these patients, BAFF may play a role
in breaching tolerance.
Materials and Methods
Ethics Statement
Mice were housed in a Canadian Council on Animal Care
(CCAC) approved facility and all experiments were performed
under the University Health Network Animal Care Committee
approved protocol #123.
Mice
NZB mice were purchased from Harlan-Sprague-Dawley
(Blackthorne, England). C57BL/6 (B6) mice and B6 mice
expressing transgenes encoding sHEL (ML5) or IgM/IgD heavy
and light chains specific for HEL (MD4; IgTg) were purchased
from The Jackson Laboratory (Bar Harbor, ME) [22]. Transgenes
were backcrossed onto the NZB background using the speed
congenic technique [51]. Double Tg (dTg) mice that expressed
both Ig and sHEL transgenes were produced by intercrossing IgTg
and sHEL mice. Mice were housed in specific pathogen free
microisolators at the Toronto Western Hospital animal facility.
ELISA and ELISpot Assays
Levels of anti-HEL IgM
a Ab and BAFF were measured by
ELISA, using commercially available Ab (R&D Systems).
Recombinant soluble mouse BAFF (Apotech, Switzerland) was
used to generate a standard curve and sera from BAFF Tg mice (a
generous gift from Dr. J. Gommerman) as a positive control. Ab-
producing cells were detected by ELISpot, as previously described
[31].
Flow cytometry staining and analysis
Erythrocyte-depleted spleen or bone marrow cells were stained
and analyzed as previously described [11]. The following directly
conjugated mAbs were purchased from BD: biotin-conjugated
anti-B220 (RA3-6B2), -IgM
a (DS-1), -CD24 (M1/69), PE-
conjugated anti-IgM
a (DS-1), -CD23 (B3B4), -CD24 (M1/69),
-CD138 (281-2), -B220, allophycocyanin-conjugated anti-CD19
(1D3), –CD21 (7G6), FITC-conjugated anti-CD21, and hamster
IgG controls. Biotinylated polyclonal rabbit anti-HEL Ab was
purchased from Rockland (Gilbertsville, PA), FITC-anti-BAFF-R
from R&D, and all isotype controls from Caltag. Allophycocyanin-
or PerCP-conjugated streptavidin (BD) was used to reveal
biotinylated Ab staining.
Immunofluorescent staining of tissue sections
Cryostat spleen sections (5 mm) were fixed and stained as
previously described [31]. Tissue fluorescence was visualized using
a Zeiss Axioplan 2 imaging microscope (Oberkochen, Germany).
In-vitro assays of B cell proliferation and CD86
upregulation
B220
+ splenic cells were sorted using a MoFlow instrument
(Cytomation Inc., CO). For proliferation assays, 5610
4 B cells
were cultured in triplicate in media alone or a submitogenic
concentration of LPS (50 ng/ml) with various concentrations of
HEL (0–1000 ng/ml). B cell proliferation was measured by [
3H]-
thymidine incorporation. For induction of CD86 expression,
5610
5 sorted B cells or T cell-depleted splenocytes from IgTg or
dTg mice were incubated in culture media alone or containing
HEL (1 mg/ml) at 37uC overnight. Cultured cells were stained
with anti-B220, -IgM
a, and -CD86 mAb.
Measurement of intracellular Bim and Bcl-2 expression
B cells were purified from the spleens of non-Tg, IgTg or dTg
mice by negative selection using a Dynal Mouse B cell Negative
Isolation Kit (Invitrogen), and incubated at 37uC for 20 or 96 hr in
media alone or containing HEL (100 ng/ml), BAFF (40 ng/ml) or
a combination of HEL and BAFF. Cells were stained with anti-
B220 or -IgM
a, -CD21, -CD24, and PE-conjugated anti-BCL-2
(3F11;BD) or hamster control (A19-3;BD) Ab to assess Bcl-2
expression, or anti-CD19 and rat anti-mouse Bim (eBioscience),
followed by allophycocyanin-conjugated anti-rat IgG (BD) FITC
to assess Bim, The cells were fixed and permeabilized prior to
intracellular staining using Cytofix/Cytoperm (BD).
Adoptive transfers
Splenocytes were depleted of T cells and labelled with CFSE
(Molecular Probes) prior to transfer, as previously described [31].
To block BAFF, recipient mice were given as single intra-
peritoneal injection with 160 mg TACI-Ig (R&D) or PBS one day
before adoptive transfer. To deplete CD4
+ T cells, recipient mice
were given two intra-peritoneal injections with 0.5 mg anti-CD4
Ab or PBS 5 days and one day before donor cell transfer.
CD4
+ cell depletion
Anti-CD4 mAb was purified as previously described [31].
Starting at 5–6 weeks of age NZB dTg mice were given two intra-
peritoneal injections with 0.5 mg anti-CD4 Ab or PBS spaced 3
days apart and this treatment was repeated every 3 weeks. This
was sufficient to deplete .95% of CD4
+ T cells.
BAFF mRNA expression
RNA was purified from 10–14 wk old mice using an RNeasy
Mini Kit (Qiagen, Switzerland), treated with DNAseI (Invitrogen),
and reverse transcribed into cDNA (Applied Biosystems, CA).
Quantitative real-time PCR was performed with SYBR Green
Figure 5. Heightened survival response of NZB dTg B cells to BAFF in-vitro. (A) Up-regulation of Bcl-2 in NZB IgTg and dTg B cells. B cells
isolated from B6 (open bars) or NZB (filled bars) IgTg or dTg mice were incubated with media alone or media containing HEL (100 ng/ml), BAFF
(40 ng/ml), or a combination of both, for 20 or 96 h at 37uC. The percent Bcl-2 positive cells was determined by flow cytometry gating on the B220
+
population. Results shown are for a single mouse from each strain and are representative experiment of four independent experiments in which a
total of 2 nTg, 5 IgTg, 7 dTg B6 mice, and 3 nTg, 6 IgTg, 4 dTg NZB mice were examined. (B) Enhanced expression of Bcl-2 in all B cell subsets of NZB
IgTg or dTg B cells after incubation with HEL and BAFF. Cells were isolated and incubated for 96 h at 37uC, as outlined in (A). The percent Bcl-2
positive cells was determined by flow cytometry gating on the B220
+ population and using CD21 and CD24 antibodies to subset B cells, as shown in
Table 1. (C) Scatterplots showing the proportion of BAFF-R
+ cells in various B cell subsets in B6 (open circles) and NZB (closed circles), IgTg and dTg
mice, gated as in (B). Background staining with a relevant isotype control was extremely low, and similar in B6 and NZB mice. Asterisks indicate the
significance level for comparison between B6 and NZB mice as determined by the Mann-Whitney test: * p,0.05, ** p,0.005, *** p,0.0005.
doi:10.1371/journal.pone.0011691.g005
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system (Applied Biosystems). Primer sequences were designed to
span exon-to-exon for beta actin (b-actin, TTGCTGACAG-
GATGCAGAAG and GTACTTGCGCTCAGGAGGAG) and
BAFF (TTCCATGGCTTCTCAGCTTT and CGTCCCCAAA-
GACGTGTACT). Gene expression was analyzed using the
relative standard curve method where BAFF expression was
normalized to b-actin.
Statistics
Comparisons of differences between groups of mice were
performed using the Mann-Whitney non-parametric test, or a two
way ANOVA followed with Bonferroni post-hoc analysis as
indicated in figure legends.
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